Sugi Predict

Sugi Predict / Compounds / SCHEMBL379892

SCHEMBL379892

SCHEMBL379892

CC(C)(C)OC(=O)NCCc1ccc(C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.54
▸ CA1 P00915 2/20 0.54
▸ NAMPT P43490 1/20 0.53
▸ MAPT P10636 2/20 0.49
▸ ESRRG P62508 3/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ IDO1 P14902 1/20 0.47
▸ ESRRB O95718 1/20 0.47
▸ CTSK P43235 1/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ FABP2 P12104 1/20 0.45
▸ PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211997 0.91 CA1 (0.52) CA2CA1NAMPTMAPTESRRG
SCHEMBL2328583 0.90 TDP1 (0.51) CA2CA1MAPTSIGMAR1TDP1
SCHEMBL12511497 0.88 CA2 (0.52) CA2CA1NAMPTMAPTESRRG
SCHEMBL3868210 0.88 CA2 (0.54) CA2CA1NAMPTMAPTESRRG
SCHEMBL7808431 0.87 CA2 (0.56) CA2CA1NAMPTMAPTESRRG
SCHEMBL1936202 0.87 MGLL (0.55) CA2CA1NAMPTMAPTESRRG
SCHEMBL28151195 0.86 IDO1 (0.47) CA2CA1NAMPTMAPTIDO1
SCHEMBL8171226 0.86 RAB9A (0.68) NAMPTMAPTESRRGNPC1RAB9A
SCHEMBL572740 0.86 IDO1 (0.60) CA2CA1NAMPTMAPTNPC1
SCHEMBL2511243 0.85 CA2 (0.55) CA2CA1NAMPTMAPTESRRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates AMBRX, INC. (US) 2026-03-10 — — US disclosed
EP-3814355-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2025-12-24 — — EP disclosed
US-12454520-B2 Protein degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-10-28 — — US disclosed
US-12358951-B2 Cyclic peptide antibiotics GENENTECH, INC. (US) 2025-07-15 — — US disclosed
US-20250195462-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2025-06-19 — — US disclosed
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 — — US disclosed
CN-113454086-B Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2025-03-14 — — CN disclosed
US-20240408408-A1 FAP-TARGETED NEUTRON CAPTURE AGENTS, AND USES AND FORMULATIONS RELATED THERETO TRUSTEES OF TUFTS COLLEGE 2024-12-12 — — US disclosed
CN-115666575-B Compounds and uses thereof 福宏治疗公司 2024-12-10 — — CN disclosed
WO-1996033982-A1 PIPERAZINONES USEFUL AS INHIBITORS OF PLATELET AGGREGATION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-10-31 — — WO disclosed
US-5550131-A ANTITHROMBOTIC AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-08-27 — — US disclosed
US-5541343-A ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS KARL THOMAE GMBH (DE) 1996-07-30 — — US disclosed
WO-1996004267-A1 NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1996-02-15 — — WO disclosed
EP-0643072-A1 2-Piperazinone compounds and their use Takeda Chemical Industries, Ltd. (JP) 1995-03-15 — — EP disclosed
CN-1098409-A 2-piperazinone compounds and application thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-02-08 — — CN disclosed
US-5294713-A Inhibiting cell adhesion TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-03-15 — — US disclosed
US-5231102-A Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME, LTD. (GB) 1993-07-27 — — US disclosed
EP-0529858-A1 2-Piperazinone compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1993-03-03 — — EP disclosed
EP-0386839-A2 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1990-09-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358951-B2 Cyclic peptide antibiotics NPPA, LNPEP, CLPP CA2 3912/4885CA1 4539/4885NAMPT 1876/4885
US-12454520-B2 Protein degraders and uses thereof MDM2, CUL1, PSMG3 CA2 4683/4885CA1 4388/4885NAMPT 2548/4885
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates TLR3, TLR2, TLR1 CA2 2367/4885CA1 3426/4885NAMPT 1712/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 CA2 2967/4885CA1 4691/4885NAMPT 1802/4885
US-20240408408-A1 FAP-TARGETED NEUTRON CAPTURE AGENTS, AND USES AND FORMULATIONS RELATED THERETO FAP, FIBP, FGFR1 CA2 3271/4885CA1 4489/4885NAMPT 14/4885
US-20250195462-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CA2 74/4885CA1 2923/4885NAMPT 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.